Chemomab Therapeutics Ltd. Royalty Expense
Chemomab Therapeutics Ltd. (CMMB) reported Royalty Expense of $1.02 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-23.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RoyaltyExpense · last filed 2026-03-23
- Chemomab Therapeutics Ltd. royalty expense for fiscal 2020 was $1.18M.
| Period end | Royalty Expense 12 month |
|---|---|
| 2025-12-31 | $1.02M 20-F · filed 2026-03-23 |
| 2024-12-31 | $418.00K 20-F · filed 2026-03-23 |
| 2023-12-31 | $4.83M 20-F · filed 2026-03-23 |
| 2022-12-31 | $5.22M 20-F · filed 2025-04-04 |
| 2021-12-31 | $2.59M 20-F · filed 2024-03-28 |
| 2020-12-31 | $1.18M 10-K · filed 2022-03-30 |